Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Puerto Rico Technology Today.
Press releases published on August 6, 2025
Veeco Reports Second Quarter 2025 Financial Results
Second Quarter 2025 Highlights: Revenue of $166.1 million, compared with $175.9 million in the same period last year GAAP net income of $11.7 million, or $0.20 per diluted share, compared with $14.9 million, or $0.25 per diluted share in the same period …
Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2025, …
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioritization of obesity as lead indication for NMRA-215, a …
Sprout Social Announces Second Quarter 2025 Financial Results
CHICAGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced financial results for its second quarter ended June …
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights
First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic sclerosis Continued execution and enrollment progress with …
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback $303.4 million cash, cash …
electroCore Announces Second Quarter 2025 Financial Results
Net sales of $7.4 million increased 20% vs. Q2’2024; YTD net sales of $14.1 million increased 22% vs. first half of 2024 Cash, cash equivalents, restricted cash, and marketable securities of $7.4 million as of June 30, 2025 Company to host a conference …
red violet Announces Second Quarter 2025 Financial Results
BOCA RATON, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced financial results for the quarter ended June 30, 2025. “We are pleased to report another strong …
Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
Revenue grew 32% year-over-year, driven by increased product sales and service revenue Launched new high-throughput Proteograph® ONE assay and SP200 automation instrument REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a …
HilleVax Reports Second Quarter 2025 Financial Results
BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2025. Second …
Cerence Announces Third Quarter Fiscal 2025 Results; Revenue and Profitability Exceed High End of Guidance
Headlines Revenue of $62.2 million; Net cash provided by operating activities of $23.7M; Free cash flow of $16.1 million marks fifth consecutive positive quarter Company raises and narrows full fiscal year guidance for revenue, adjusted EBITDA and free …
LiveRamp Announces Results for First Quarter FY26
Revenue up 11% year-over-year Record-High Operating Margin for Q1 Share Repurchases totaled $30 million SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- LiveRamp® (NYSE: RAMP), a leading data collaboration platform, today announced its financial results …
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded base and depth of prescribers and led to a meaningful …
ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update
2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted EBITDA(1) of $50.8 Million, a 59% YoY Increase …
Senseonics Holdings, Inc. Reports Second Quarter Financial Results
Generated Q2 revenue of $6.6 million, representing year-over-year growth of 37% Achieved a 79% increase in U.S. new patient starts over prior year GERMANTOWN, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical …
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
– Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement – – Further …
Snail, Inc. Sets Second Quarter 2025 Conference Call for Wednesday, August 13, 2025 at 4:30 p.m. ET
CULVER CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, will hold a conference call and webcast on …
Cytek Biosciences Reports Second Quarter 2025 Financial Results
FREMONT, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2025. Second …
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, …